Exero Medical’s xBar Post-Operative Tissue Healing Monitoring and Analysis System Demonstrates Positive Study Results
Study published in the Journal of Surgical Research
The findings are the basis of a multi-center clinical trial currently ongoing at
Rabin Medical Center, Sheba Medical Center, Shamir Medical Center and Kaplan Medical Center
Or Yehuda, Israel, July 12, 2022 — A pre-clinical study using Exero Medical’s post-operative tissue healing monitoring technology, demonstrated for the first time, an ability to use measurable tissue changes to detect, early on, serious post-op complications such as leaks.
The results were published in the peer reviewed Journal of Surgical Research. Click here to view the full article.
The outcomes of this controlled study are the basis for the current clinical study of xBar that enrolled its first patient in March 2022 at the Beilinson Campus at Rabin Medical Center. It is also ongoing at Sheba Medical Center, Shamir Medical Center and Kaplan Medical Center.
“The article provides the proof of concept we needed in vitro and in vivo for accurate monitoring of tissue healing using the body’s naturally generated signals,” said Exero Medical CEO Dr. Erez Shor. “We believe that this first of its kind data will enable us to personalize and optimize post-op care, allowing for shorter hospitalizations in patients who recover quickly and life-saving early interventions in patients who develop serious complications.”
“The data collected in this pre-clinical trial showed diagnostic sensitivity for a gastrointestinal leak with potential clinical utility in the postoperative detection of early intra-abdominal sepsis. As further studies are most definitely required and encouraged, we are looking forward to the results of the current clinical study in progress and to hopefully having an impact on many lives in the future,” said Dr. Matan Ben-David, co-founder of Exero Medical.
xBar is a sensor designed to track tissue healing from the surgical site following an operation so that the surgeon can treat the patient early to avoid further complications.
The technology is first being utilized for GI surgeries but can be developed for other surgeries in the future.
About Exero Medical
Exero was founded in 2018 by MEDX Xelerator, an Israeli Innovation Authority incubator, and Clalit HMO, the largest HMO in Israel. Exero Medical’s goal is to provide high quality, actionable post-surgery tissue healing that can save lives, improve prognosis and reduce cost. The company’s flagship product, xBar, which has an FDA Breakthrough Designation, is intended for the early detection of anastomotic leaks following gastrointestinal (GI) surgeries, a $2 billion market. It is currently being tested in a multi-center clinical trial.
Exero Medical is backed by seed investment from the MEDX Xelerator, Boston Scientific, MEDX Ventures, Intellectual Ventures, and CBG Group. The company is presently engaged in a series A financing round.
For more information, please visit https://www.exeromedical.com/.
Must Have Communications
On behalf of Exero Medical